Clinical Trial Update: Bortezomib and Vorinostat as Maintenance Therapy After Autologous Stem Cell Transplant in Treating Patients With Non-Hodgkin Lymphoma [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating bortezomib plus vorinostat as maintenance after autologous stem cell transplant in non-Hodgkin lymphoma showed results posted; aims to …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• B-cell Non-hodgkin Lymphoma
• Diffuse Large B-cell Lymphoma
• Follicular Lymphoma
• Mantle Cell Lymphoma
• Non-hodgkin Lymphoma
• T-cell Non-hodgkin Lymphoma

Drugs mentioned

• Bortezomib (bortezomib)
• Vorinostat (vorinostat)

Snippet

Sponsor: Fred Hutchinson Cancer Center | Conditions: Adult Diffuse Large B-Cell Lymphoma, B-Cell Non-Hodgkin Lymphoma | Phase 2 | Status: COMPLETED | Results posted: 2017-05-10